摘要
目的:探讨维布妥昔单抗所致不良反应(ADR)的发生规律和临床表现特点,为其临床安全、合理用药提供参考。方法:检索中国知网、万方数据、维普网、中国生物医学文献数据库、Embase、PubMed数据库,收集上市后维布妥昔单抗致ADR的报道并进行统计分析。结果:共纳入文献24篇,涉及患者254例,所致ADR包括神经系统损害(30.13%)、血液系统损害(26.50%)、免疫功能紊乱(9.62%)、皮肤及附件损害(8.97%)、全身性损害(8.33%)等,其中以周围神经病变(29.70%)和中性粒细胞减少(21.37%)最为常见,其次为感染、输液反应、转氨酶升高、血小板减少、皮疹等。大部分患者经停药或减量后好转或痊愈,有9例患者因ADR而死亡,包括间质性肺病(3例)、肺炎(2例)、进行性多灶性白质脑病(2例)、心力衰竭(1例)、急性肝损伤(1例)。结论:临床医生、药师应重视维布妥昔单抗致ADR的危害性,临床使用中应加强对患者的监护,及时发现ADR并积极处理,确保患者用药安全。
Objective:To analyze the situation and clinical characteristics of adverse drug reactions induced by brentuximab vedotin,so as to provide reference for clinical safe and rational drug use.Methods:By searching the literature in CNKI,Wanfang,database,VIP,CBM,Embase,and PubMed,the adverse drug reaction cases after the marketing of brentuximab vedotin were collected and statistically analyzed.Results:A total of 24 literatures were involved and 254 patients were included.Adverse drug reactions induced by brentuximab vedotin mainly involved nervous system damage(30.13%),blood system damage(26.50%),immune dysfunction(9.62%),skin and subcutaneous tissue disorders(8.97%),systemic reaction(8.33%),with the specific performance of peripheral neuropathy,neutropenia,infections,infusion reaction,elevated transaminase levels,thrombocytopenia,rashes,and so on.Most of the patients with adverse reactions had good prognosis.Nine cases of death were reported,including interstitial lung disease(n=3),pneumonia(n=2),progressive multifocal leukoencephalopathy(n=2),heart failure(n=1)and acute liver injury(n=1).Conclusion:The doctors and pharmacists should pay attention to the adverse drug reactions by brentuximab vedotin.The adverse drug reaction monitoring should be strengthened,with the adverse drug reactions detected and dealt in time,so as to ensure the medication safety of patients.
作者
吕曼
陈静
陈喆
LÜMan;CHEN Jing;CHEN Zhe(Department of Pharmacy,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Clinical Pharmacy,Sichuan Mental Health Center/The Third Hospital of Mianyang,Mianyang 621000,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2023年第15期1585-1592,共8页
Chinese Journal of New Drugs
关键词
维布妥昔单抗
药品不良反应
文献分析
brentuximab vedotin
adverse drug reaction
literature analysis
作者简介
吕曼,女,药师,研究方向:临床药学。E-mail:lyumans@163.com;通讯作者:陈喆,女,副主任药师,研究方向:临床药学。E-mail:gigichen79@126.com。
